Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Clin Mol Hepatol. 2025;31(Suppl):S94-S111. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811

View: 4032 Download: 316 Web of Science: 3 Crossref: 5

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2025;31(Suppl):S51-S75. Published online June 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246

View: 6182 Download: 229 Web of Science: 3 Crossref: 3

Epidemiology of metabolic dysfunction-associated steatotic liver disease

Zobair M. Younossi, Markos Kalligeros, Linda Henry

Clin Mol Hepatol. 2025;31(Suppl):S32-S50. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0431

View: 12527 Download: 1,836 Web of Science: 38 Crossref: 47

Special Issue

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2025;31(Suppl):S1-S31. Published online February 19, 2025

DOI: https://doi.org/10.3350/cmh.2025.0045

View: 1140 Download: 144 Crossref: 1

Reply to Correspondence

Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):e226-e227. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0128

View: 831 Download: 24

Correspondence

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(2):e208-e209. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1171

View: 911 Download: 20

Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):e186-e188. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0079

View: 577 Download: 33 Crossref: 1

Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”

Ji Won Han, Dae Won Jun

Clin Mol Hepatol. 2025;31(2):e152-e154. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.1160

View: 767 Download: 27

Letter to the Editor

Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Hai Xu, Yong Zhou, Huikun Wu

Clin Mol Hepatol. 2025;31(2):e125-e127. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1087

View: 837 Download: 24 Crossref: 1

Editorial

Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Nahee Hwang, Sungsoon Fang

Clin Mol Hepatol. 2025;31(2):631-634. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0066

View: 826 Download: 41 Crossref: 2

Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):628-630. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0036

View: 976 Download: 38 Crossref: 2

A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):610-614. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1099

View: 806 Download: 39 Crossref: 2

Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”

Myeung Gi Choi, Na Young Lee, Ja Hyun Koo

Clin Mol Hepatol. 2025;31(2):592-595. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0971

View: 1110 Download: 67

Original Article

GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in metabolic dysfunction-associated steatohepatitis livers

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Xiao-Chen Ma, Chen-He Yi, Bao-Rui Tao, Bo Zhang, Yue Ma, Guo Zhang, Rui Zhang, Yan Geng, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):409-425. Published online December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0657

View: 1892 Download: 250 Crossref: 7

Correspondence

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

Baokai Sun, Likun Zhuang

Clin Mol Hepatol. 2025;31(1):e67-e69. Published online September 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0744

View: 1031 Download: 77

Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”

Young Eun Chon, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e61-e63. Published online October 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0878

View: 980 Download: 28

Letter to the Editor

Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes

Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen

Clin Mol Hepatol. 2025;31(1):e35-e38. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0719

View: 1156 Download: 66 Web of Science: 1 Crossref: 1

Editorial

TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

Andrea Caddeo, Rosellina M. Mancina

Clin Mol Hepatol. 2025;31(1):293-296. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0703

View: 1248 Download: 106 Crossref: 3

MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”

Rex Wan-Hin Hui, Lung-Yi Mak

Clin Mol Hepatol. 2025;31(1):290-292. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0630

View: 1002 Download: 29 Crossref: 2

Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Won Sohn

Clin Mol Hepatol. 2025;31(1):277-280. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0823

View: 1236 Download: 41 Crossref: 1

Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Yangyue Zhang, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2025;31(1):264-267. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0766

View: 1279 Download: 41 Crossref: 1

Original Article

Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis

Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(1):227-239. Published online November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0564

View: 1764 Download: 139 Crossref: 6

Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments

Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian

Clin Mol Hepatol. 2025;31(1):179-195. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0359

View: 1754 Download: 159 Web of Science: 1 Crossref: 2

USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination

Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li

Clin Mol Hepatol. 2025;31(1):147-165. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0478

View: 3679 Download: 570 Web of Science: 1 Crossref: 2

Review

Bioactive metabolites: A clue to the link between MASLD and CKD?

Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun

Clin Mol Hepatol. 2025;31(1):56-73. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0782

View: 2312 Download: 189

Roles of X-box binding protein 1 in liver pathogenesis

Jihoon Tak, Yun Seok Kim, Sang Geon Kim

Clin Mol Hepatol. 2025;31(1):1-31. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0441

View: 2511 Download: 175

Special Topic

A new Korean nomenclature for steatotic liver disease

Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2024;30(Suppl):S214-S216. Published online July 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0467

View: 1863 Download: 93 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan

Clin Mol Hepatol. 2024;30(4):1039-1041. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0801

View: 1218 Download: 28

Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2024;30(4):1033-1034. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0360

View: 1441 Download: 29

Correspondence

The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”

Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li

Clin Mol Hepatol. 2024;30(4):1019-1022. Published online July 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0471

View: 1784 Download: 60

1 | 2 | 3 |

Viewed By 9995	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7136	MAFLD: How is it different from NAFLD?
Viewed By 5121	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4654	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4607	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 322	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 304	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 205	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 103	Non-alcoholic fatty liver disease: Definition and subtypes

Search